Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by danghill14on Mar 18, 2021 2:41pm

153 Views

Post# 32827760

CBD products for pets

Sponsored post Other organizations are currently conducting research that could likely shed light on how useful CBD is for some disorders in dogs. For more details, go here!

The following study was reported so far: 16 dogs with confirmed osteoarthritis were given 2mg/kg of CBD twice daily for four weeks. At weeks 2 and 4, there were less pain and development in activity when compared to placebo treatment (fake treatment), with no observable side effects.

A pilot study of 9 dogs with epilepsy treated with CBD showed a reduction in seizure frequency in 89%. A larger study involving 60 dogs is underway. Check disclaimer on profile and landing page.

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season